Loading
Every dated change on the records linked to Renal cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
With lenvatinib, advanced renal cell carcinoma with a clear cell component
With belzutifan, advanced renal cell carcinoma with a clear cell component
When this page itself was last checked or edited.
Adjuvant clear-cell RCC with pembrolizumab
Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
Active surveillance, partial nephrectomy (usually robotic), or thermal ablation depending on growth, comorbidity, and biopsy; renal mass biopsy increasingly used. (NCCN 2A)
Final progression-free survival 14.
Primary endpoint not met (ASCO GU 2026).
DFS significantly improved vs pembrolizumab (interim; HR presented ASCO GU 2026).
A milestone in how this cancer is treated.
Advanced RCC after PD-1/PD-L1 and VEGF-TKI
Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023)
PFS HR 1.
PFS HR 0.
A milestone in how this cancer is treated.
VHL-associated RCC, CNS haemangioblastoma, pNET
First-line advanced RCC with nivolumab (CheckMate 9ER)
Advanced RCC with pembrolizumab; endometrial cancer with pembrolizumab
Relapsed/refractory advanced RCC after ≥2 prior systemic therapies
PFS 23.
DFS HR 0.
Cabozantinib lengthened progression-free survival compared with sunitinib in metastatic papillary renal cell carcinoma; the crizotinib and savolitinib arms closed for futility.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Sunitinib alone was non-inferior to cytoreductive nephrectomy plus sunitinib for overall survival in intermediate- and poor-risk metastatic clear cell renal cell carcinoma.
8-year OS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Nivolumab improved overall survival and response rate over everolimus in previously treated clear cell renal cell carcinoma; approved in November 2015.
A milestone in how this cancer is treated.
Metastatic renal cell carcinoma
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.